A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food

This is a Phase I, open-label, randomized, 2-period, 2-treatment, crossover study in healthy participants. This study will measure the impact of food on the pharmacokinetics (PK) of combined zibotentan/dapagliflozin for the to be marketed fixed-dose combination (FDC) formulation (study intervention). The study will comprise of, (i) A screening period (ii) 2 treatment periods (iii) A final follow-up visit. All participants will receive a single dose of the study intervention once under fasted condition (Treatment A) and once under fed condition (Treatment B).